|
(Health-NewsWire.Net, April 09, 2021 ) According to research report the cancer biomarkers market to reach USD 20.4 billion by 2022. and is estimated to grow at a CAGR of 12.2% during the forecast period.
Ask for PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
The major players operating in the cancer biomarkers market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US).
The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market.
The genetic biomarkers segment is expected to grow at the highest CAGR during the forecast period
Based on biomarker type, the market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers). During the forecast period, the genetic biomarkers segment is estimated to grow at the highest CAGR majorly due to advancements in high-throughput technologies, such as next-generation sequencing, which have enhanced the speed and accuracy of genetic biomarker discovery and diagnosis.
The breast cancer segment accounted for the largest share of the cancer biomarkers market in 2016
Based on cancer type, the market is segmented into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkins lymphoma, kidney, and other cancers (such as cervical, multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers). The breast cancer segment accounted for the largest share of this market owing to the high and growing prevalence of breast cancer, increasing awareness about breast cancer, rising number of breast cancer screening programs, and growing research on breast cancer.
Request Free Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202
North America accounted for the largest share of the cancer biomarkers market in 2017, followed by Europe. Growth in the developed markets of North America and Europe is primarily driven by the high adoption of advanced technologies like NGS, increasing number of research studies for the discovery and development of novel biomarkers, presence of a large number of pharmaceutical companies, rising funding and investments from public and private organizations, and increasing use of biomarkers in patient stratification and drug development process.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
